Theravance Biopharma, Inc. Operating Cash Flow
Theravance Biopharma, Inc. (TBPH) reported Operating Cash Flow of $66.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.96M, a 103.35% decline year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $73.28M, a 70.26% increase year-over-year.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.06M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.51M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $238.54M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$11.54M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$27.00M.
- Theravance Biopharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$186.99M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $66.31M 10-Q · filed 2026-08-11 | $60.25M derived: sum of 3 quarters · filed 2026-08-11 | $53.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $73.28M 10-Q · filed 2026-05-07 | $67.22M derived: sum of 2 quarters · filed 2026-05-07 | $60.71M derived: sum of 3 quarters · filed 2026-05-07 | $268.78M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$6.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$12.57M derived: sum of 2 quarters · filed 2026-03-23 | $195.50M derived: sum of 3 quarters · filed 2026-08-11 | $238.54M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$6.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $201.57M derived: sum of 2 quarters · filed 2026-08-11 | $244.60M 10-Q · filed 2025-11-12 | $243.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $208.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $251.11M 10-Q · filed 2026-08-11 | $250.21M derived: sum of 3 quarters · filed 2026-08-11 | $245.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $43.04M 10-Q · filed 2026-05-07 | $42.14M derived: sum of 2 quarters · filed 2026-05-07 | $36.94M derived: sum of 3 quarters · filed 2026-05-07 | $32.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$902.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$6.10M derived: sum of 2 quarters · filed 2026-03-23 | -$10.51M derived: sum of 3 quarters · filed 2026-03-23 | -$11.54M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$9.61M derived: sum of 2 quarters · filed 2025-11-12 | -$10.63M 10-Q · filed 2025-11-12 | -$11.49M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$5.44M 10-Q · filed 2025-08-13 | -$6.29M derived: sum of 3 quarters · filed 2025-08-13 | -$8.78M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$1.02M 10-Q · filed 2025-05-12 | -$1.88M derived: sum of 2 quarters · filed 2025-05-12 | -$4.36M derived: sum of 3 quarters · filed 2025-05-12 | -$16.80M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$854.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$3.34M derived: sum of 2 quarters · filed 2025-03-07 | -$15.78M derived: sum of 3 quarters · filed 2025-03-07 | -$27.00M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$14.92M derived: sum of 2 quarters · filed 2024-11-14 | -$26.14M 10-Q · filed 2024-11-14 | -$150.20M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$12.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$23.66M 10-Q · filed 2024-08-08 | -$147.71M derived: sum of 3 quarters · filed 2024-08-08 | -$169.85M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$11.22M 10-Q · filed 2024-05-15 | -$135.28M derived: sum of 2 quarters · filed 2024-05-15 | -$157.41M derived: sum of 3 quarters · filed 2024-05-15 | -$172.14M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$124.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$146.19M derived: sum of 2 quarters · filed 2024-03-01 | -$160.92M derived: sum of 3 quarters · filed 2024-03-01 | -$186.99M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$22.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$36.87M derived: sum of 2 quarters · filed 2023-11-09 | -$62.94M 10-Q · filed 2023-11-09 | -$105.37M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$14.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$40.80M 10-Q · filed 2023-08-09 | -$83.23M derived: sum of 3 quarters · filed 2023-08-09 | -$128.68M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$26.07M 10-Q · filed 2023-05-10 | -$68.50M derived: sum of 2 quarters · filed 2023-05-10 | -$113.95M derived: sum of 3 quarters · filed 2023-05-10 | -$164.06M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$42.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$87.88M derived: sum of 2 quarters · filed 2023-03-01 | -$137.99M derived: sum of 3 quarters · filed 2023-03-01 | -$207.86M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$45.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$95.56M derived: sum of 2 quarters · filed 2022-11-09 | -$165.42M 10-Q · filed 2022-11-09 | -$230.35M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$50.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$119.98M 10-Q · filed 2022-08-08 | -$184.90M derived: sum of 3 quarters · filed 2023-03-01 | -$261.93M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$69.86M 10-Q · filed 2022-05-06 | -$134.79M derived: sum of 2 quarters · filed 2023-03-01 | -$211.82M derived: sum of 3 quarters · filed 2023-03-01 | -$265.17M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$64.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$141.96M derived: sum of 2 quarters · filed 2023-03-01 | -$195.30M derived: sum of 3 quarters · filed 2023-03-01 | -$250.40M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$77.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$130.38M derived: sum of 2 quarters · filed 2021-11-08 | -$185.48M 10-Q · filed 2021-11-08 | -$249.83M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$53.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$108.45M 10-Q · filed 2021-08-05 | -$172.80M derived: sum of 3 quarters · filed 2022-02-28 | -$217.42M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$55.10M 10-Q · filed 2021-05-06 | -$119.45M derived: sum of 2 quarters · filed 2022-02-28 | -$164.07M derived: sum of 3 quarters · filed 2022-02-28 | -$212.10M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$64.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$108.97M derived: sum of 2 quarters · filed 2022-02-28 | -$157.00M derived: sum of 3 quarters · filed 2022-02-28 | -$238.20M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$44.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$92.65M derived: sum of 2 quarters · filed 2020-11-09 | -$173.84M 10-Q · filed 2020-11-09 | -$226.02M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$48.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$129.22M 10-Q · filed 2020-08-10 | -$181.40M derived: sum of 3 quarters · filed 2021-02-26 | -$230.38M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$81.19M 10-Q · filed 2020-05-08 | -$133.37M derived: sum of 2 quarters · filed 2021-02-26 | -$182.35M derived: sum of 3 quarters · filed 2021-02-26 | -$243.88M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$52.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$101.16M derived: sum of 2 quarters · filed 2021-02-26 | -$162.69M derived: sum of 3 quarters · filed 2021-02-26 | -$112.87M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$48.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$110.51M derived: sum of 2 quarters · filed 2019-11-08 | -$60.69M 10-Q · filed 2019-11-08 | -$104.89M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$61.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$11.71M 10-Q · filed 2019-08-05 | -$55.91M derived: sum of 3 quarters · filed 2020-02-27 | -$118.21M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $49.83M 10-Q · filed 2019-05-10 | $5.62M derived: sum of 2 quarters · filed 2020-02-27 | -$56.68M derived: sum of 3 quarters · filed 2020-02-27 | -$101.20M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$44.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$106.50M derived: sum of 2 quarters · filed 2020-02-27 | -$151.03M derived: sum of 3 quarters · filed 2020-02-27 | -$201.05M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$62.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$106.82M derived: sum of 2 quarters · filed 2018-11-08 | -$156.85M 10-Q · filed 2018-11-08 | -$184.96M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$44.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$94.55M 10-Q · filed 2018-08-02 | -$122.66M derived: sum of 3 quarters · filed 2019-02-28 | -$135.10M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$50.03M 10-Q · filed 2018-05-09 | -$78.14M derived: sum of 2 quarters · filed 2019-02-28 | -$90.57M derived: sum of 3 quarters · filed 2019-02-28 | |
| 2016-12-31 | -$28.11M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$40.55M derived: sum of 2 quarters · filed 2019-02-28 | -$98.99M 10-K · filed 2019-02-28 | |
| 2016-09-30 | -$12.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$70.88M 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | -$58.44M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$168.86M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |